Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: Behavioural characterization and implications for the treatment of CNS disorders

Behavioural Pharmacology

Volumn 14, Issue 4, 2003, Pages 257-277

  Spooren, Will ^a   Ballard, T ^a   Gasparini, F ^b   Amalric, M ^c   Mutel, V ^d   Schreiber, R ^e  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CNRS   (France)

^d ADDEX PHARMACEUTICALS   (Switzerland)

^e ROCHE BIOSCIENCE   (United States)

Author keywords

Agonists; Antagonists; Behaviour; G protein coupled receptors; Metabotropic glutamate receptors; Mouse; Neurodegenerative disorders; Psychiatric disorders; Rat

Indexed keywords

(3 ETHYL 2 METHYLQUINOLIN 6 YL)(4 HYDROXYCYCLOHEXYL)METHANONE; (4 METHOXYPHENYL)(6 METHOXYQUINAZOLIN 4 YL)AMINE; 1 AMINO 1,3 CYCLOPENTANEDICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 CHLORO 5 HYDROXYPHENYLGLYCINE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 (2 METHYL 1,3 THIAZOL 4 YLETHYNYL)PYRIDINE; 3 [1 AMINO 1 CARBOXY 2 (9H XANTHEN 9 YL)ETHYL]CYCLOBUTANECARBOXYLIC ACID; 3,5 DIMETHYL 1H PYRROLE 2,4 DICARBOXYLIC ACID 2 PROPYL ESTER; 4 (1,2,2 TRIMETHYLPROPYL) ESTER; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 4 CARBOXY 3 HYDROXYPHENYLGLYCINE; 4 CARBOXYPHENYLGLYCINE; 5 METHYLENE 6A NAPHTHALEN 2 YLMETHYLHEXAHYDROCYCLOPENTA[C]FURAN 1 ONE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; 7 HYDOXYIMINOCYCLOPROPAN[B]CHROMEN 1A CARBOXYLIC ACID ETHYL ESTER; ALPHA METHYL 4 CARBOXYPHENYLGLYCINE; AZETIDINE 2,4 DICARBOXYLIC ACID; BAY 36 7620; CHROMENE DERIVATIVE; DIZOCILPINE; EGLUMETAD; LY 314582; LY 368375; LY 456236; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; QUISQUALIC ACID; R 128494; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; BEHAVIOR; BRAIN REGION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; MENTAL DISEASE; MOLECULAR CLONING; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SYNAPSE;

EID: 0042868860     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000081783.35927.8f     Document Type: Review

References (218)

1. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S (1994). Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 79:365-375.
2. Akbar MT, Rattray M, Powell JF, Meldrum BS (1996). Altered expression of group I metabotropic receptors in the hippocampus of amygdala-kindled rats. Mol Brain Res 43:105-116.
3. Amalric M, Koob GF (1987). Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction-time performance in rats. J Neurosci 7:2129-2134.
4. Amalric M, Baunez C, Nieoullon A (1995). Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction-time deficits induced by dopamine inactivation? Behav Pharmacol 6:508-519.
5. Amalric M, Breysse N, Baunez C (2002). Allevation of akinesia after chronic metabotropic glutamate receptor 5 blockade is not potentiated by a combined NMDA antagonist treatment in 6-OHDA treated rats. Neuropharmacology 43:273.
6. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor 5 rodent brain: in vitro and in vivo characterisation. J Pharmacol Exp Ther 303:1044-1051.
7. Ango F, Pin JP, Tu JC, Xiao B, Worley PF, Bockaert J, Fagni L (2000). Dendritic and axonal targeting of type 5 metabotropic glutamate receptor (mGluR5) is regulated by homer 1 proteins and neuronal excitation. J Neurosci 20:8710-8716.
8. Ango F, Prezeau L, Müller T, Worley PF, Pin JP, Bockaert J, Fagni L (2001). Agonist-independent activation of mGluRs by the intracellular interacting protein, homer. Nature 411:962-965.
9. Aronica E, van Vliet EA, Mayboroda OA, Troost D, da Silva FH, Gorter JA (2000). Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci 12:2333-2344.
10. Aronica E, Jansen GH, van Veelen CWM, Ramkema M, Gorter JA, Troost D (2002). Expression and cell distribution of Group-I and Group-II metabotropic receptor subtypes in focal cortical dysplasia. Neuropharmacology 43:274.
11. Attarian S, Amalric M (1997). Microinfusion of the metabotropic glutamate receptor agonist 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid into the nucleus accumbens induces dopamine-dependent locomotor activation in the rat. Eur J Neurosci 9:809-816.
12. Aultman JM, Moghaddam B (2001). Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology 153:353-364.
13. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2001). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
14. Ballard TM, Ouagazzal A-M, Woltering T, Adam G, Mutel V, Higgins GA (2001a). Metabotropic glutamate group II receptor compounds in animal models of psychosis. Behav Pharmacol 12(suppl 1):S4.
15. Ballard TM, Kew JNC, Richards JG, Woltering TJ, Adam G, Nakanishi S, et al. (2001b). Pharmacologial and genetic evidence for an important modulatory role of mGlu2 receptors on cognitive function. Soc Neurosci Abstr 27:705.11.
16. Balschun D, Wetzel W (1998). Inhibition of group I metabotropic receptors blocks spatial learning in rats. Neurosci Lett 249:41-44.
17. Balschun D, Wetzel W (2002). Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol Biochem Behav 73:375-380.
18. Balschun D, Manahan-Vaughan D, Wagner T, Behnisch T, Reymann KG, Wetzel W (1999). A specific role for group I mGluRs in hippocampal LTP and hippocampus-dependent spatial learning. Learning Memory 6:138-152.
19. Bao WL, Williams AJ, Faden AI, Tortella FC (2001). Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res 922:173-179.
20. Battaglia G, Fornai F, Busceti CL, Bovolin P (2002). Metabotropic glutamate receptor ligands are protective in experimental animal models of Parkinson's disease. Neuropharmacology 43:275.
21. Baude A, Nusser Z, Roberts JDB, Mulvihill E, McIlhinney RAJ, Somogyi P (1993). The metabotropic glutamate receptor (mGluR1a) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron 11:771-787.
22. Bessis A-S, Bertrand HO, Galvez T, De Colle C, Pin JP, Acher F (2000). 3D-model of the extracellular domain of the type 4a metabotropic glutamate receptor: new insights into the activation process. Protein Sci 9:2200-2209.
23. Bhave G, Karim F, Carlton SM, Gereau RW IV (2001). Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci 4:417-423.
24. Blaabjerg M, Vawter MP, Fang L, Zimmer J, Baskys A (2002). Neuroprotection by Group I metabotropic glutamate receptors: effect on NMDA-stimulated currents and gene expression. Neuropharmacology 43:277.
25. Bond A, O'Neill MJ, Hicks CA, Monn JA, Lodge D (1998). Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport 9:1191-1193.
26. Bordi F, Ugolini A (1999). Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 59:55-79.
27. Bourson A, Juillet V, Petit N (1999). Effect of LY354740 a group II mGluR agonist on PCP and amphetamine behaviours. Behav Pharmacol 10(Suppl 1):S10.
28. Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H (2000). Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci 20:3085-3094.
29. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343.
30. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002). Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669-5678.
31. Bristow LJ, Campbell LD, Rodriguez D, Baccei C, Anderson JJ, Varney MA (2002). The mGluR2/3 agonist LY379268 attenuates the hyperactivity and increased prefrontal cortex and hippocampal glutamate release induced by NMDA receptor antagonists in the rat. Neuropharmacology 43:279.
32. Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney (2002a). Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Pharmacol 16:2241-2244.
33. Brodkin J, Busse C, Sukoff SJ, Varney MA (2002b). Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73:359-366.
34. Bruijnzeel AW, Stam R, Wiegant VM (2001). LY354740 attenuates the expression of long-term behavioral sensitization induced by a single session of foot shocks. Eur J Pharmacol 426:77-80.
35. Bruno V, Battaglia G, Kingston A, O'Neill MJ, Catania MV, Di Grezia R, Nicoletti F (1999). Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4-carboxyphenyl-glycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 38:199-207.
36. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, et al. (2000). Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39:2223-2230.
37. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iori P, De Blasi A, et al. (2001). Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013-1033.
38. Camon L, Vives P, de Vera N, Martinez E (1998). Seizures and neuronal damage induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5-dihydroxyphenylglycine. J Neurosci Res 51:339-348.
39. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 41:237-260.
40. Carroll FY, Stolle A, Beart P, Voerste A, Brabet I, Mauler F, et al. (2001). BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 59:965-973.
41. Cartmell J, Monn JA, Schoepp DD (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170.
42. Cartmell J, Monn JA, Schoepp DD (2000a). Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148:423-429.
43. Cartmell J, Monn JA, Schoepp DD (2000b). Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedeberg's Arch Pharmacol 361:39-46.
44. Cartmell J, Monn JA, Schoepp DD (2000c). The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400:221-224.
45. Chapman AG, Yip PK, Yap JS, Quinn LP, Tang E, Harris JR, Meldrum BS (1999). Anticonvulsant actions of LY367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol 368:17-24.
46. Chapman AG, Nanan K, Meldrum BS, Schreiber R, De Vry J, Müller T (2000a). Anticonvulsant activity in mice of BAY36-7620, a novel, selective mGluR1 antagonist. Soc Neurosci Abstr 26:1650.
47. Chapman AG, Nanan K, Williams M, Meldrum BS (2000b). Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39:1567-1574.
48. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, et al. (2001). Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4:873-874.
49. Christoffersen GRJ, Christensen LH, Harrington NR, Macphail EM, Riedel G (1999a). Task-specific enhancement of short-term, but not long-term, memory by class I metabotropic glutamate receptor antagonist 1-aminoindan-1,5-dicarboxylic acid in rats. Behav Brain Res 101:215-226.
50. Christeffersen GRJ, Christensen LH, Hammer P, Vang M (1999b). The class I metabotropic glutamate receptor antagonist, AIDA, improves short-term and impairs long-term memory in a spatial task for rats. Neuropharmacology 38:817-823.
51. Conn PJ, Pinn JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 37:205-237.
52. Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, Bordi F, et al. (1994). Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 372:237-243.
53. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, et al. (2003). 3-[(2-Methyl-1,3-thiazel-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.
54. Costantino G, Pellicciari R (1996). Homology modeling of metabotropic glutamate receptors (mGluRs): structural motifs affecting binding models and pharmacological profile of mGluR1 agonists and competitive antagonists. J Med Chem 39:3998-4006.
55. Costantino G, Macchiarulo A, Pellicciari R (2001). Homology model of the closed, functionally active, form of the amino terminal domain of mGluR1. Bioorg Med Chem 9:847-852.
56. Cozzi A, Lombardi G, Leonardi P, Attucci S, Peruginelli F, Pellicciari R, Moroni F (1997). AIDA, a group I metabotropic glutamate receptor antagonist reduces the ischemia-induced neuronal loss. Soc Neurosci Abstr 23:788.
57. De Blasi A, Conn PJ, Pin JP, Nicoletti F (2001). Molecular determinants of metabotropic glutamate receptor signalling. Trends Pharmacol Sci 22:114-120.
58. De Vry J, Horvath E, Schreiber R (2001). Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY36-7620. Eur J Pharmacol 428:203-214.
59. De Vry J (2002). Behavioral pharmacology of metabotropic glutamate1 receptors antagonists. Neuropharmacology 43:284.
60. Dingledine R, Borges K, Bowie D, Traynelis SF (1999). The glutamate receptor ion channels. Pharmacol Rev 51:7-61.
61. Dogrul A, Ossipov MH, Lai J, Malan TP Jr, Porreca F (2000). Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR5) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 292:115-118.
62. Doherty AJ, Palmer MJ, Henley JM, Collinridge GL, Jane DE (1997). RS-2-Chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36:265-267.
63. Faden AI, Movseyan VA (2002). Group I mGluR modulation provides protection against beta-amyloid-induced neuronal death in rat primary neuronal cultures. Neuropharmacology 43:285.
64. Faden AI, O'Leary DM, Fan L, Bao WL, Mullins PGM, Movsesyan VA (2001). Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma. Exp Neurol 167:435-444.
65. Fendt M, Schmid S (2002). Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur J Neurosci 15:1535-1541.
66. A-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 15:76-82.
67. Fisher K, Coderre TJ (1998). Hyperalgesia and allodynia induced by intrathecal (RS)-dihydroxyphenylglycine in rats. Neuroreport 9:1169-1172.
68. Fitzjohn SM, Irving AJ, Palmer MJ, Harvey J, Lodge D, Collingridge GL (1996). Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neurosci Lett 203:211-213.
69. Fotuhi M, Sharp AH, Glatt CE, Hwang PM, Von Krosigk M, Snyder SH, Dawson TM (1993). Differential localization of phosphoinositide-linked metabotropic glutamate recepor (mGluR1) and the inositol 1,4,5-triphosphate receptor in rat brain. J Neurosci 13:2001-2012.
70. Fundytus ME, Fisher K, Dray A, Henry JL, Coderre TJ (1998). In vivo antinociceptive activity of anti-rat mGluR1 and mGluR5 antibodies in rats. Neuroreport 9:731-735.
71. Fundytus ME, Yashpal K, Chabot JG, Osborne MG, Lefebvre CD, Dray A, et al. (2001). Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1) alleviates pain and restores opioid efficacy after nerve injury in rats. Br J Pharmacol 132:354-367.
72. Galvez T, Parmentier ML, Joly C, Malitschek B, Kaupmann K, Kuhn R, et al. (1999). Mutagenesis and modeling of the GABAB receptor extracellular domain support a venus flytrap mechanism for ligand binding. J Biol Chem 274:13362-13369.
73. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, et al. (1999). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
74. Gasparini F, Floersheim P, Flor PJ, Heinrich M, Inderbitzin W, Ott D, et al. (2001). Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco 56:95-99.
75. Gasparini F, Kuhn R, Pin JP (2002). Allosteric modulators of Group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2:43-49.
76. Gewirtz JC, Marek GJ (2000). Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23:569-576.
77. Geyer MD, Markou A (1995.) Animal models of psychiatric disorders. In: Bloom, Kupfer (editors): Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press; pp. 794-795.
78. Ghasemzadeh MB, Nelson LC, Lu XY, Kalivas PW (1999). Neuroadaptations in ionotropic and metabotropic glutamate receptor mRNA produced by cocaine treatment. J Neurochem 72:157-165.
79. Grauer SM, Marquis KL (1999). Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology 141:405-412.
80. Grillon C, Cordove J, Levine LR, Morgan CA (2003). Anxiolytic effects of a novel Group II metabotropic glutamate receptor agonist (LY354740) in the fear potentiated startle paradigm in humans. Psychopharmacology (in press).
81. Harrison AA, Gasparini F, Markou A (2002). Nicotine potentiation of brain stimulation reward reversed by DHβE and SCH 23390, but not by eticlopride, LY314582 or MPEP in rats. Psychopharmacology 160:56-66.
82. Heidinger V, Manzerra P, Wang XQ, Strasser U, Yu SP, Choi DW, Behrens MM (2002). Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci 22:5452-5461.
83. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1997). LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 36:1511-1516.
84. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998). Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for Group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660.
85. Henrich-Noack P, Hatton CD, Reymann KG (1998). The mGlu receptor ligand (S)-4C3HPG protects neurons after global ischaemia. Neuroreport 9:985-988.
86. Henry SA, Conquet F, Geyer MA (2001). Prepulse inhibition deficit in mGluR5 knockout mice after multiple manipulations. Soc Neurosci Abstr 27:983.14.
87. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002). The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582 augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199-1209.
88. Hermans E, Challiss RAJ (2001). Structural, signalling and regulatory properties of group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. J Biochem 359:465-484.
89. Hölscher C, Gigg J, O'Mara SM (1999). Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. Neurosci Biobehav Rev 23:399-410.
90. Houamed KM, Kijper JL, Gilbert TL, Haldeman BA, Mulvihill ER, Almers W, Hagen FS (1991). Cloning, expression and gene structure of a G protein-coupled glutamate receptor from rat brain. Science 252:1318-1321.
91. Hudson LJ, Bevan S, McNair K, Gentry C, Fox A, Kuhn R, Winter J (2002). Metabotropic glutamate receptor 5 upregulation in A-fibers after spinal nerve injury: 2-methyl-6-(phenylethynyl)-pyridine (MPEP) reverses the induced thermal hyperalgesia. J Neurosci 22:2660-2668.
92. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 10:1301-1308.
93. Jensen AA, Greenwood JR, Brauner-Osborne H (2002). The dance of the clams: twists and turns in the family C GPCR homodimer. Trends Pharmacol Sci 23:491-493.
94. Johnson BG, Wright RA, Valli MJ, Massey SM, Monn JA, Schoepp DD (2002a). Binding, functional and behavioral effects of novel mGlu2/3 receptor agonists. Neuropharmacology 43:290.
95. Johnson K, Dieckman D, Britton T, Johnson M, Jagdmann E, Monn J, et al. (2002b). Selective, non-amino acid allosteric mGlu2 receptor potentiators inhibit dural plasma protein extravasation; a potential role in the treatment of migraine. Neuropharmacology 43:291.
96. Kalra AB, Simmons RMA, Clark BP, Kingston AE, Iyengar S (2001). Effects of LY367385, a selective mGlu1 receptor antagonist, in the capsaicin and carrageenan models of persistent pain. Soc Neurosci Abstr 27:53.16.
97. 14C]-2-deoxyglucose autoradiographic study. J Neurosci 17:4415-4425.
98. Kenny PJ, Gasparini F, Markou A (2002). Group II metabotropic glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal. Neuropharmacology 43:292.
99. Kim JH, Vezina P (1998). Metabotropic glutamate receptors in the rat nucleus accumbens contribute to amphetamine-induced locomotion. J Pharmacol Exp Ther 284:317-322.
100. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, et al. (1998). LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 31:1-12.
101. Kinney GG, Wittmann M, Bristow LJ, Campbell UC, Conn PJ (2002). Behavioral consequences of mGluR5 and NMDA receptor antagonist interaction: implications for schizophrenia. Neuropharmacology 43:292.
102. Klodzińska A, Chojnacka-Wójcik E, Pałucha A, Branski P, Popik P, Pilc A (1999). Potential anti-anxiety, anti-addictive effects of LY354740, a selective group II glutamate metabotropic receptor agonist in animal models. Neuropharmacology 38:1831-1839.
103. Klodzińska A, Bijak M, Chojnacka-Wójcik E, Kroczka B, Swiader M, Czuczwar SJ, Pilc A (2000). Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn Schmiedeberg's Arch Pharmacol 361:283-288.
104. Klodzińska A, Chojnacka-Wójcik E, Wieronska J, Pilc A (2002). Anxiolytic-like effects of MPEP, the selective metabotropic glutamate receptor 5-mGluR5-antagonist, in rats. Pharmacological analysis. Neuropharmacology 43:292.
105. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, et al. (2001). Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci 98:13402-13407.
106. Konieczny J, Ossowska K, Wolfarth S, Pilc A (1998). LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedeberg's Arch Pharmacol 358:500-502.
107. Krystal J, Abi-Saab W, Perry E, D'Souza D, Liu N, McDougall L, et al. (2002). Modulation of ketamine-induced working memory deficits in healthy human subjects by the group II metabotropic agonist, LY354740. Proceedings of the 41st Annual Meeting of the American College of Neuropsychopharmacology, 8-12 December, San Juan, Puerto Rico.
108. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, et al. (2000). Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407:971-977.
109. Lesage ASJ, Bischoff F, Van Beijsterveldt L, Meert T, Steckler T, Ashton D (2002). Novel, centrally active mGlu1 antagonists: in vitro and in vivo pharmacology. Neuropharmacology 43:295.
110. 2 challenge in patients diagnosed with panic disorder. Neuropharmacology 43:294.
111. Levine LR, Gaydos B, Potter WZ, Tollefson GD (2002b). The mGlu2/3 receptor agonist, LY354740, demonstrates anxiolytic activity in GAD. Proceedings of the 41st Annual Meeting of the American College of Neuropsychopharmacology, 8-12 December, San Juan, Puerto Rico.
112. Li L, Tomlinson R, Wang Y, Tsui HC, Chamberlain MJ, Johnson MP, et al. (2002). A novel series of potent and selective non-competitive antagonists of metabotropic glutamate receptor 1. Neuropharmacology 43:295.
113. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, et al. (1999). CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
114. Löscher W (1998). Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 54:721-741.
115. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, Roder JC (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17:5196-5205.
116. Lujan R, Nusser Z, Roberts JD, Shigemoto R, Somogyi P (1996). Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci 8:1488-1500.
117. Mabire D, Coupa S, Adelinet C, Pons A, Simonnet Y, Venet M, et al. (2002). Synthesis, structure-activity relationship and receptor pharmacology of a new series of quinoline derivatives acting as selective non-competitive mGluR1 antagonists. Neuropharmacology 43:296.
118. Maione S, Oliva P, Marabese I, Palazzo E, Rossi F, Berrino L, et al. (2000). Periaqueductal gray matter metabotropic glutamate receptors modulate formalin-induced nociception. Pain 85:183-189.
119. Manahan-Vaughan D, Schuetz K (2002). Differential participation of metabotropic glutamate receptor mGlu1 and mGlu5 in spatial learning and hippocampal long-term potentiation in vivo. Neuropharmacology 43:297.
120. Manahan-Vaughan D, Herrero I, Reymann KG, Sanchez-Prieto JSO (1999). Presynaptic group I metabotropic glutamate receptors may contribute to the expression of long-term potentiation in the hippocampal CA1 region. Neuroscience 94:71-82.
121. Martin LJ, Blackstone CD, Huganir R, Price DL (1992). Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9:259-270.
122. Masu M, Tanabe Y, Tsuchida K, Shigemototo R, Nakanishi S (1991). Sequence and expression of a metabotropic glutamate receptor. Nature 349:760-765.
123. Mathis C, Ungerer A (1999). The retention deficit induced by (RS)-α-methyl-4-carboxyphenylglycine in a lever-press learning task is blocked by selective agonists of either group I or group II metabotropic glutamate receptors. Exp Brain Res 129:147-155.
124. Meldrum B (2002). Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res 50:33-40.
125. Meldrum BS, Chapman AG (1999). Excitatory amino acid receptors and antiepileptic drug development. Adv Neurol 79:965-978.
126. Merlin LR (1999). Group I mGluR-mediated silent induction of long-lasting epileptiform discharges. J Neurophysiol 82:1078-1081.
127. Merlin LR (2002). Differential roles for mGluR1 and mGluR5 in the persistent prolongation of epileptiform bursts. J Neurophysiol 8:621-625.
128. Merlin LR, Wong RK (1996). Role of group I metabotropic glutamate receptors in the patterning of epileptiform activities in vitro. J Neurophysiol 78:539-544.
129. Micheli F, Di Fabio R, Cavanni P, Corsi M, Donati D, Ratti E, et al. (2002). New pyrroles as mGluR1 antagonists. Neuropharmacology 43:296.
130. Mills CD, Johnson KM, Hulsebosch CE (2002). Group I metabotropic glutamate receptors in spinal cord injury: roles in neuroprotection and the development of chronic central pain. J Neurotrauma 19:23-42.
131. Moghaddam B, Adams B (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352.
132. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, et al. (1997). Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537.
133. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, et al. (1999). Synthesis, pharmacological characterization and molecular modelling of heterobicyclic amino acids related to LY354740: Identification of two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42:1027-1040.
134. Moore NA, Rees G, Monn JA (1999). Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats. Behav Pharmacol 10:319-325.
135. Moroni F, Lombardi G, Thomsen C, Leonardi P, Attucci S, Peruginelli F, et al. (1997). Pharmacological characterisation of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J Pharmacol Exp Ther 281:721-729.
136. Müller T, De Vry J, Schreiber R, Horvath E, Mauler F, Stolle A, Lowe D (2000). BAY36-7620, a selective metabotropic glutamate receptor1 antagonist with anticonvulsant and neuroprotective properties. Soc Neurosci Abstr 26:1650.
137. Nadlewska A, Car H, Wisniewska RJ, Wisniewski K (2002). Behavioral effects of the selective blockade of metabotropic glutamate receptor subtype 5 in experimental hypoxia. Pol J Pharmacol 54:95-102.
138. Nakanishi S (1994). The molecular diversity of glutamate receptors. Prog Clin Biol Res 390:85-98.
139. Neugebauer V, Zinebi F, Russel R, Gallagher JP, Shinnick-Gallagher P (2000). Cocaine and kindling alter the sensitivity of group II and group III metabotropic glutamate receptors in the central amygdala. J Neurophysiol 84:759-770.
140. Nicoletti F, Ladarola M, Wroblenski JT, Costa E (1986). Excitatory amino acid recognition sites coupled with inositol phospholipid metabolism: developmental changes and interaction with alpha 1-adrenoreceptors. Proc Natl Acad Sci. USA 81:1931-1935.
141. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T (1996). Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurol Sci 19:267-271.
142. Nielsen KS, Macphail EM, Riedel G (1997). Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats. Eur J Pharmacol 326:105-108.
143. Nitsch RM, Deng A, Wurtman RJ, Growdon JH (1998). Metabotropic glutamate receptor subtype mGluR1 α stimulates the secretion of the amyloid β-protein precursor ectodomain. J Neurochem 69:704-712.
144. Ohishi H, Ogawa-Meguro R, Shigemoto R, Kaneko T, Nakanishi S, Mizuno N (1994). Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 13:55-66.
145. Ohno M, Watanabe S (1998). Enhanced N-methyl-D-aspartate function reverses working memory failure induced by blockade of group I metabotropic glutamate receptors in the rat hippocampus. Neurosci Lett 240:37-40.
146. O'Leary DM, Movsesyan V, Vicini S, Faden AI (2000). Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 131:1429-1437.
147. O'Meara GF, Newman RJ, Reynolds DS, Bristow LJ, Dawson GR (2002). Behavioural evaluation of mGluR5 knock-out mouse Third FENS Forum abstract 87.6, p. 232.
148. Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Wolfarth S, Pilc A (2000). The role of glutamate receptors in antipsychotic drug action. Amino Acids 19:87-94.
149. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A (2001). Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41:413-420.
150. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001). Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25:565-575.
151. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, et al. (2000). The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
152. Petersen S, Bomme C, Baastrup C, Kemp A, Christoffersen GR (2002). Differential effects of mGluR1 and mGlur5 antagonism on spatial learning in rats. Pharmacol Biochem Behav 73:381-389.
153. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ (1996). The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique
154. Petralia RS, Wang YX, Singh S, Wu C, Shi L, Wei J, Wenthold RJ (1997). A monoclonal antibody shows discrete cellular and subcellular localizations of mGluR1a metabotropic glutamate receptors. J Chem Neuroanat 13:77-93.
155. Pilc A, Klodzińska A, Branski P, Nowak G, Patucha A, Szewczyk B, et al. (2002). Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43:181-187.
156. Pin JP, De Colle C, Bessis AS, Acher F (1999). New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol 375:277-294.
157. Popik P, Wrobel M (2002). Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology 43:1210-1217.
158. Quiocho FA, Ledvina PS (1996). Atomic structure and specificity of bacterial periplasmic receptors for active transport and chemotaxis: variation of common themes. Mol Microbiol 20:17-25.
159. Rahman S, Neuman RS (1996). Characterisation of metabotropic glutamate receptor-mediated facilitation of N-methyl-D-aspartate depolarization of neocortical neurons. Br J Pharmacol 117:675-683.
160. Randall TS, Davies A, Collinridge G (2002). Pharmacological characterisation of the modulation of non-synaptic epileptiform activity by Group I mGluRs. Neuropharmacology 43:310.
161. Richter-Levin G, Errington ML, Maegawa H, Bliss TV (1994). Activation of metabotropic glutamate receptors is necessary for long-term potentiation in the dentate gyrus and for spatial learning. Neuropharmacology 33:853-857.
162. Riedel G (1996). Function of metabotropic glutamate receptors in learning and memory. Trends Neurol Sci 19:219-224.
163. Robbe D, Bockaert J, Manzoni OJ (2002). Metabotropic glutamate receptor 2/3-dependent long-term depression in the nucleus accumbens is blocked in morphine withdrawn mice. Eur J Neurosci 16:2231-2235.
164. Roche K, Tu JC, Petralia RS, Xiao B, Wenthold RJ, Worley PF (1999). Homer 1b regulates the trafficking of group I metabotropic glutamate receptors. J Biol Chem 274:25953-25957.
165. Rodrigues SM, Bauer EP, Farb CR, Schafe GE, LeDoux JE (2002). The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J Neurosci 22:5219-5229.
166. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355:455-469.
167. Romano C, Yang WL, O'Malley KL (1996). Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271:28612-28616.
168. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ (2000). Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 88:427-435.
169. Sacaan AI, Monn JA, Schoepp DD (1991). Intrastriatal injection of a selective metabotropic excitatory amino acid receptor agonist induces contralateral turning in the rat. J Pharmacol Exp Ther 259:1366-1370.
170. Sacaan AI, Bymaster FP, Schoepp DD (1992). Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J Neurochem 59:245-251.
171. Salt TE, Binns KE (2000). Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 100:375-380.
172. Schoepp DD, Sacaan AI (1994). Metabotropic glutamate receptors and neuronal degenerative disorders. Neurobiol Aging 15:261-263.
173. Schoepp DD, Monn JA, Marek GJ, Aghajanian G, Moghaddam B (1999). LY354740: A systemically active mGlu2/mGlu3 receptor agonist. CNS Drug Reviews 5:1-12.
174. Schreiber R, Lowe D, Voerste A, De Vry J (2000). LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 388:R3-R4.
175. Schröder UH, Schreiber R, Stolle A, Müller T, Jork R, Reymann KG (2002). A novel mGluR1 antagonist differentially affects synaptic plasticity in CA1 of rat hippocampal slices and impairs acquisition in the water maze task. Neuropharmacology 43:307.
176. Schultz B, Fendt M, Gasparini F, Lingenhohl K, Kuhn R, Koch M (2001). The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 41:1-7.
177. Schwarz RD, Dickerson M, Gillespie K, Kinsora J, Lotarski S (2002). mGluR group I antagonists for the treatment of anxiety. Neuropharmacology 43:308.
178. Sekiyama N, Hayashi Y, Nakanishi S, Jane DE, Tse HW, Birse EF, Watkins JC (1996). Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br J Pharmacol 117:1493-1503.
179. Shannon HE, Peters SC (2002). Anticonvulsant effects of the selective mGlu1 receptor antagonist LY456236 in mice and rats. Neuropharmacology 43:308.
180. Shekhar A, Keim SR (2000). LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39:1139-1146.
181. Shigemoto R, Mizuno N (2000.) Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analysis. In: Ottersen, Storm-Mathisen (editors): Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier; pp. 63-98.
182. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N (1993). Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci lett 163:53-57.
183. Simmons RMA, Katner JS, Clark BP, Kingston AE, Iyengar S (2001). Effects of a selective mGlu1 receptor antagonist, LY367385, in rodent models of persistent pain. Soc Neurosci Abstr 27:53.15.
184. Sladeczek F, Pin JP, Recasens M, Bockaert J, Weiss S (1985). Glutamate stimulates inositol phosphate formation in striatal neurons. Nature 317:717-719.
185. Smith ID, Beninger RJ (1996). Contralateral turning caused by metabotropic glutamate receptor stimulation in the dorsal striatum is reversed by MCPG, TTX, and cis-flupenthixol. Behav Neurosci 110:282-289.
186. Spooren WP, Gasparini F, Bergmann R, Kuhn R (2000a). Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 406:403-410.
187. Spooren WPJM, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R (2000b). Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397:R1-R2.
188. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. (2000c). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295:1267-1275.
189. Spooren WP, Gasparini F, Salt TE, Kuhn R (2001). Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 22:331-337.
190. Spooren WPJM, Schoeffter P, Gasparini F, Kuhn R, Gentsch C (2002a). Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435:161-170.
191. Spooren W, Vivian J, Ballard T (2002b). Anxiolytic-like effects of the selective mGlu5 receptor antagonist MPEP in punished responding. Neuropharmacology 43:309.
192. Sugiyama H, Ito I, Hirono C (1987). A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 325:531-533.
193. Swanson CJ, Kalivas PW (2000). Regulation of locomotor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area. J Pharmacol Exp Ther 292:406-414.
194. Swanson CJ, Schoepp DD (2002). The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviours in monoamine-depleted rats. J Pharmacol Exp Ther 303:919-927.
195. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-153.
196. Tang E, Yip PK, Chapman AG, Jane DE, Meldrum BS (1997). Prolonged anticonvulsant action of glutamate metabotropic receptor agonists in inferior colliculus of genetically epilepsy-prone rats. Eur J Pharmacol 327:109-115.
197. Tatarczynska E, Klodzińska A, Chojnacka-Wojcik E, Pałucha A, Gasparini F, Kuhn R, Pilc A (2001a). Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430.
198. Tatarczynska E, Klodzińska A, Kroczka B, Chojnacka-Wójcik E, Pilc A (2001b). The anti-anxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology 158:94-99.
199. Thomsen C, Dalby NO (1998). Roles of metabotropic glutamate receptor subtypes in modulation of pentylenetetrazole-induced seizure activity in mice. Neuropharmacology 37:1465-1473.
200. Thomsen C, Klitgaard H, Sheardown M, Jackson HC, Eskesen K, Jacobsen P, et al. (1994). (S)-4-carboxy-3-hydroxyphenylglycine, an antagonist of metabotropic glutamate receptors (mGluR)1a and an agonist of mGluR2, protects against audiogenic seizures in DBA/2 mice. J Neurochem 62:2492-2495.
201. Tizzano JP, Griffey KI, Schoepp DD (1993). Induction or protection of limbic seizures in mice by mGluR subtype-selective agonists. Neuropharmacology 34:1063-1067.
202. Tizzano JP, Griffey KI, Johnson JA, Fix AS, Helton DR, Schoepp DD (1995). Intracerebral 1S,3R-1-amino-cyclopentane-1,3-dicarboxylic acid ((1S,3R)-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists. Neurosci Lett 162:12-16.
203. Tizzano JP, Griffey KI, Schoepp DD (2002a). The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367-374.
204. Tizzano JP, Griffey KI, Valli MJ, Massey SM, Monn JA, Schoepp DD (2002b). Novel mGlu2/3 receptor agonists in the fear potentiated startle model. Neuropharmacology 43:310.
205. Vandergriff J, Rasmussen K (1999). The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 38:217-222.
206. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, et al. (1999). SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181.
207. Varney MA, Anderson J, Bradbury M, Bristow L, Brodkin J, Giravello D, et al. (2002). 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP): A potent and highly selective metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Neuropharmacology 43:311.
208. Vezina P, Kim JH (1999). Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain. Neurosci Biobehav Rev 23:577-589.
209. Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A et al. (2001a). Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 40:1-9.
210. Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, et al. (2001b). mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 40:10-19.
211. Wichmann T, DeLong MR (1998). Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am 9:223-236.
212. Williams DL, O'Brien JA, Lemaire W, Chen T.-B, Chang RSL, Jacobson MA, et al. (2002). DFB, an allosteric potentiator of mGluR5 [Abstract]. Neuropharmacology 43.
213. Wilsch VW, Behnisch T, Jager T, Reymann KG, Balschun D (1998). When are class I metabotropic glutamate receptors necessary for long-term potentiation? J Neurosci 18:6071-6080.
214. Wolfarth S, Konieczny J, Lorenc-Koci E, Ossowska K, Pilc A (2000). The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids 19:95-101.
215. Wong RK, Bianchi R, Taylor GW, Merlin LR (1999). Role of metabotropic glutamate receptors in epilepsy. Adv Neurol 79:685-698.
216. Xiao B, Tu JC, Worley PF (2000). Homer: a link between neural activity and glutamate receptor function. Curr Opin Neurobiol 10:370-374.
217. Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, Katsuura G, et al. (1996). Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 273:645-647.
218. Young MR, Blackburn Munro G, Dickinson T, Johnson MJ, Anderson H, Nakalembe I, Fleetwood Walker SM (1998). Antisense abration of type I metabotropic glutamate receptor mGluR1 inhibits spinal nociceptive transmission. J Neurosci 18:10180-10188.